vs
Side-by-side financial comparison of Doximity, Inc. (DOCS) and Immunocore Holdings plc (IMCR). Click either name above to swap in a different company.
Doximity, Inc. is the larger business by last-quarter revenue ($185.1M vs $104.5M, roughly 1.8× Immunocore Holdings plc). On growth, Immunocore Holdings plc posted the faster year-over-year revenue change (24.3% vs 9.8%). Over the past eight quarters, Doximity, Inc.'s revenue compounded faster (25.2% CAGR vs 21.7%).
Doximity is an online networking service for medical professionals. Launched in 2010, the platform offers its members curated medical news, telehealth tools, and case collaboration.
Immunocore is a global commercial-stage biotechnology company, based in Oxfordshire, which researches and develops biological drugs using soluble T-cell receptor technology.
DOCS vs IMCR — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $185.1M | $104.5M |
| Net Profit | $61.6M | — |
| Gross Margin | 89.9% | 97.4% |
| Operating Margin | 38.9% | -18.8% |
| Net Margin | 33.3% | — |
| Revenue YoY | 9.8% | 24.3% |
| Net Profit YoY | -18.1% | — |
| EPS (diluted) | $0.31 | $-0.61 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $185.1M | $104.5M | ||
| Q3 25 | $168.5M | $103.7M | ||
| Q2 25 | $145.9M | $98.0M | ||
| Q1 25 | $138.3M | $93.9M | ||
| Q4 24 | $168.6M | $84.1M | ||
| Q3 24 | $136.8M | $80.2M | ||
| Q2 24 | $126.7M | $75.4M | ||
| Q1 24 | $118.1M | $70.5M |
| Q4 25 | $61.6M | — | ||
| Q3 25 | $62.1M | $-177.0K | ||
| Q2 25 | $53.3M | $-10.3M | ||
| Q1 25 | $62.5M | $5.0M | ||
| Q4 24 | $75.2M | — | ||
| Q3 24 | $44.2M | $8.7M | ||
| Q2 24 | $41.4M | $-11.6M | ||
| Q1 24 | $40.6M | $-24.4M |
| Q4 25 | 89.9% | 97.4% | ||
| Q3 25 | 90.3% | 99.5% | ||
| Q2 25 | 89.2% | 98.9% | ||
| Q1 25 | 89.5% | 99.1% | ||
| Q4 24 | 91.6% | 99.6% | ||
| Q3 24 | 90.0% | 99.4% | ||
| Q2 24 | 89.3% | 97.7% | ||
| Q1 24 | 89.4% | 99.7% |
| Q4 25 | 38.9% | -18.8% | ||
| Q3 25 | 37.8% | -6.9% | ||
| Q2 25 | 37.4% | -15.2% | ||
| Q1 25 | 35.2% | -3.9% | ||
| Q4 24 | 47.4% | -23.1% | ||
| Q3 24 | 38.8% | -10.6% | ||
| Q2 24 | 36.4% | -21.2% | ||
| Q1 24 | 35.5% | -37.6% |
| Q4 25 | 33.3% | — | ||
| Q3 25 | 36.8% | -0.2% | ||
| Q2 25 | 36.5% | -10.5% | ||
| Q1 25 | 45.2% | 5.4% | ||
| Q4 24 | 44.6% | — | ||
| Q3 24 | 32.3% | 10.9% | ||
| Q2 24 | 32.7% | -15.4% | ||
| Q1 24 | 34.4% | -34.7% |
| Q4 25 | $0.31 | $-0.61 | ||
| Q3 25 | $0.31 | $0.00 | ||
| Q2 25 | $0.27 | $-0.20 | ||
| Q1 25 | $0.31 | $0.10 | ||
| Q4 24 | $0.37 | $-0.47 | ||
| Q3 24 | $0.22 | $0.17 | ||
| Q2 24 | $0.21 | $-0.23 | ||
| Q1 24 | $0.20 | $-0.49 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $64.8M | $864.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $979.3M | $381.0M |
| Total Assets | $1.2B | $1.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $64.8M | $864.2M | ||
| Q3 25 | $169.2M | $892.4M | ||
| Q2 25 | $137.3M | $882.8M | ||
| Q1 25 | $209.6M | $837.0M | ||
| Q4 24 | $165.3M | $820.4M | ||
| Q3 24 | $184.2M | $901.3M | ||
| Q2 24 | $111.4M | $859.6M | ||
| Q1 24 | $96.8M | $832.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $438.7M | ||
| Q2 24 | — | $452.5M | ||
| Q1 24 | — | $452.5M |
| Q4 25 | $979.3M | $381.0M | ||
| Q3 25 | $1.1B | $396.6M | ||
| Q2 25 | $1.0B | $388.5M | ||
| Q1 25 | $1.1B | $378.5M | ||
| Q4 24 | $1.0B | $360.7M | ||
| Q3 24 | $961.2M | $377.8M | ||
| Q2 24 | $913.6M | $359.1M | ||
| Q1 24 | $901.4M | $359.5M |
| Q4 25 | $1.2B | $1.1B | ||
| Q3 25 | $1.3B | $1.1B | ||
| Q2 25 | $1.2B | $1.1B | ||
| Q1 25 | $1.3B | $1.0B | ||
| Q4 24 | $1.2B | $1.0B | ||
| Q3 24 | $1.1B | $1.1B | ||
| Q2 24 | $1.1B | $1.0B | ||
| Q1 24 | $1.1B | $994.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.16× | ||
| Q2 24 | — | 1.26× | ||
| Q1 24 | — | 1.26× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $60.9M | $-32.7M |
| Free Cash FlowOCF − Capex | — | $-35.5M |
| FCF MarginFCF / Revenue | — | -34.0% |
| Capex IntensityCapex / Revenue | — | 2.8% |
| Cash ConversionOCF / Net Profit | 0.99× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-15.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $60.9M | $-32.7M | ||
| Q3 25 | $93.9M | $-4.5M | ||
| Q2 25 | $62.1M | $26.0M | ||
| Q1 25 | $98.5M | $435.0K | ||
| Q4 24 | $65.2M | $-14.0M | ||
| Q3 24 | $68.3M | $21.1M | ||
| Q2 24 | $41.2M | $23.5M | ||
| Q1 24 | $63.9M | $-4.6M |
| Q4 25 | — | $-35.5M | ||
| Q3 25 | — | $-5.2M | ||
| Q2 25 | — | $25.6M | ||
| Q1 25 | — | $137.0K | ||
| Q4 24 | — | $-17.5M | ||
| Q3 24 | — | $20.3M | ||
| Q2 24 | — | $23.1M | ||
| Q1 24 | — | $-5.0M |
| Q4 25 | — | -34.0% | ||
| Q3 25 | — | -5.0% | ||
| Q2 25 | — | 26.1% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | -20.9% | ||
| Q3 24 | — | 25.3% | ||
| Q2 24 | — | 30.7% | ||
| Q1 24 | — | -7.1% |
| Q4 25 | — | 2.8% | ||
| Q3 25 | — | 0.7% | ||
| Q2 25 | — | 0.4% | ||
| Q1 25 | 0.0% | 0.3% | ||
| Q4 24 | 0.0% | 4.3% | ||
| Q3 24 | 0.0% | 1.0% | ||
| Q2 24 | 0.0% | 0.4% | ||
| Q1 24 | 0.0% | 0.6% |
| Q4 25 | 0.99× | — | ||
| Q3 25 | 1.51× | — | ||
| Q2 25 | 1.16× | — | ||
| Q1 25 | 1.58× | 0.09× | ||
| Q4 24 | 0.87× | — | ||
| Q3 24 | 1.55× | 2.42× | ||
| Q2 24 | 1.00× | — | ||
| Q1 24 | 1.57× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DOCS
| Subscription | $175.4M | 95% |
| Service Other | $9.7M | 5% |
IMCR
Segment breakdown not available.
